On the stock market since 2017, it operates in the world of health and science. It has 6,800 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
An average decline of 10% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
The stock trades 55% below its peak. The market has trimmed its expectations for the company.
There is $78.9M in the vault; even if every debt were paid off, $58.1M would remain.
A loss of $29.7M against $934.6M in annual sales. And on top of that, sales fell from the year before.
Since the drop from its peak, buyer appetite hasn’t come back.
On our five-subject report card, ALR sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: ALR has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.